(Q39306353)
Statements
Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer (English)
Takayuki Nakagawa
Shinji Takeuchi
Shigeki Nanjo
Daisuke Ishikawa
Takako Sano
Kenji Kita
Takahiro Nakamura
Yoshitaka Sekido
Toshimitsu Uenaka
1 reference